Mapping fosfomycin resistance genes across staphylococcal genomes

Antibiotic resistance research has taken a significant step forward with the publication of a comprehensive genomic survey that decodes the full repertoire of fosfomycin resistance genes hiding within staphylococcal bacteria. The study, published in Nature Communications by a research team led by Chen, Zhu and Ye and their colleagues, provides the most complete picture to date of how staphylococci — the bacterial genus that includes the notorious Staphylococcus aureus — acquire, carry and deploy genetic defenses against fosfomycin, a structurally unusual antibiotic that has long been regarded as a valuable last-line option against multidrug-resistant infections. The findings arrive at a moment of growing concern among infectious disease specialists, who have watched resistance to fosfomycin creep upward in clinical isolates and have struggled to understand the molecular machinery behind that trend.

Fosfomycin occupies a singular place in the antibiotic arsenal. Unlike the beta-lactams, macrolides and fluoroquinolones that dominate hospital formularies, fosfomycin is a phosphonic acid compound that mimics an intermediate of bacterial cell-wall synthesis. It works by covalently inactivating MurA, the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, thereby preventing bacteria from building the rigid mesh that gives their cell walls structural integrity. Because this mechanism is unlike that of any other antibiotic family in routine use, fosfomycin retains activity against many organisms that have become resistant to conventional therapies, and clinicians increasingly turn to it — often in combination regimens — when confronted with carbapenem-resistant Enterobacterales, vancomycin-resistant enterococci and difficult staphylococcal infections. The clinical value of the drug makes the spread of resistance genes a matter of urgent practical concern, not merely academic interest.

The new study set out to answer a deceptively simple question: how many distinct fosfomycin resistance genes exist in staphylococci, where are they located in the genome, and how are they moving between strains and species? To do this, the researchers assembled and systematically analyzed large collections of staphylococcal genome sequences, spanning both pathogenic species such as Staphylococcus aureus and Staphylococcus epidermidis and commensal or animal-associated relatives. Rather than relying on a single known resistance marker, the team employed a combination of homology searches, protein family clustering and structural prediction to identify every gene in these genomes that encodes an enzyme capable of chemically modifying or degrading fosfomycin. This genome-wide, comparative approach is what distinguishes the work from earlier studies that examined one or two resistance determinants in isolation.

The biological logic of fosfomycin resistance is worth unpacking, because it explains why the genomic census was necessary. Bacteria defeat fosfomycin through two broad strategies. The first is target modification: mutations in murA or in the glpT and cysB regulatory genes that control fosfomycin uptake can reduce the drug’s effectiveness without any horizontal gene transfer. The second, and more worrying from an epidemiological standpoint, is enzymatic inactivation. Three mechanistically distinct enzyme families are known to modify fosfomycin: FosA-type glutathione transferases, which open the epoxide ring of the drug by conjugating it to glutathione; FosB-type bacillithiol transferases, which perform the same ring-opening reaction using bacillithiol, the dominant low-molecular-weight thiol in gram-positive bacteria; and FosX-type hydrolases, which open the epoxide with water alone and thereby render the antibiotic harmless without consuming any cofactor. All three families catalyze the addition of a nucleophile across fosfomycin’s strained epoxide ring, destroying the electrophilic center the drug needs to attack MurA.

In staphylococci, the FosB family has historically been the dominant player, and the new genomic analysis confirms that fosB-like genes are widespread and remarkably diverse across the genus. But diversity is precisely the point of the study. By clustering the fosB homologs found across hundreds of genomes into distinct subfamilies and examining their sequence conservation, genomic context and predicted active-site residues, the researchers were able to show that staphylococci carry a far richer repertoire of fosfomycin-inactivating genes than clinical microbiology laboratories currently test for. Some of these genes sit on the bacterial chromosome, integrated into core genomic regions, while others are located on mobile genetic elements — plasmids, transposons and genomic islands — that shuttle readily between cells during conjugation, transduction or transformation. The distinction matters enormously: chromosomal resistance evolves slowly within a lineage, whereas mobile resistance can jump between species and across ecological niches in a single transfer event.

The team paid particular attention to the genomic neighborhoods surrounding resistance genes, because context often reveals history. Where a fos gene is flanked by transposase genes, insertion sequences and repeats characteristic of mobile elements, that is strong evidence that the determinant is horizontally transmissible. Where it is flanked by housekeeping genes and shares the same codon usage pattern as its host chromosome, that suggests long co-evolution. The survey found examples of both, and — critically — identified hybrid arrangements in which fos genes appear to have been mobilized in the past and subsequently stabilized in chromosomal “safe harbors.” This pattern implies a two-stage dynamic: resistance genes circulate on mobile elements, seeding new host species, and then become fixtures of those species’ chromosomes once selection pressure from antibiotic exposure makes them worth keeping. The result is a layered resistance landscape in which old acquisitions and recent transfers coexist within the same organism.

Functional validation was central to the study’s credibility. Identifying a gene by sequence similarity is one thing; proving that it confers resistance is another. The researchers expressed representative members of each identified gene family in laboratory strains and measured minimum inhibitory concentrations of fosfomycin, demonstrating that the genes genuinely protect bacteria from the drug at concentrations relevant to clinical dosing. They also characterized the enzymatic activities of the encoded proteins, confirming that FosB-family enzymes from staphylococci catalyze bacillithiol-dependent ring opening and that related enzymes employ the expected chemistry. Kinetic and structural comparisons across subfamilies revealed how subtle differences in active-site architecture tune the efficiency of fosfomycin inactivation, offering a mechanistic explanation for why some staphylococcal isolates tolerate the drug while others succumb.

The epidemiological implications of the survey are sobering. Fosfomycin resistance genes were found not only in clinical isolates of Staphylococcus aureus but also in commensal staphylococci recovered from animals, food products and environmental sources. Staphylococci are notorious for their ability to exchange genes — the spread of methicillin resistance, mediated by the SCCmec cassette, remains one of the most consequential examples of horizontal gene transfer in modern medicine. The new data suggest that fosfomycin resistance determinants may be riding the same mobile genetic infrastructure. Commensal species living on skin and mucous membranes serve as reservoirs where resistance genes can persist without obvious selective pressure, waiting for an opportunity to recombine into a pathogenic strain. The study’s finding that resistance genes cluster phylogenetically in ways inconsistent with simple vertical inheritance supports the view that staphylococci constitute a connected gene pool in which fosfomycin defense is a shared, transferable resource.

For clinicians and diagnostic developers, the study carries a practical warning. Routine susceptibility testing for fosfomycin is inconsistent across laboratories, and molecular surveillance programs typically screen for only a handful of canonical resistance markers. A staphylococcal strain harboring a divergent fosB subfamily would evade such screens while remaining fully resistant in the patient. The authors’ catalog of resistance genes, organized by family and diagnostic-relevant sequence signatures, provides a foundation for building more comprehensive PCR panels and metagenomic screening pipelines. It also supplies benchmark sequences for machine-learning approaches that predict resistance phenotype directly from genome assemblies, an area of growing interest as whole-genome sequencing becomes routine in clinical microbiology.

The study also informs drug development. Understanding the enzymatic chemistry that bacteria use to destroy fosfomycin opens the door to rational inhibitor design — molecules that mimic fosfomycin’s epoxide but irreversibly bind the resistance enzymes instead, thereby restoring the antibiotic’s activity. Structure-guided inhibitors of FosA and FosB have shown promise in preclinical work, and a more complete map of the sequence and structural diversity of these enzymes, which the new survey provides, is essential for designing inhibitors broad enough to neutralize the full range of variants bacteria might deploy. There is also a screening angle: the catalog can be used to predict, before a compound ever reaches the clinic, which staphylococcal lineages are likely to be intrinsically resistant due to their genomic endowment.

The research comes amid broader anxiety about the post-antibiotic era. Fosfomycin has been in clinical use since the 1970s but was long relegated to uncomplicated urinary tract infections; the rise of carbapenem-resistant gram-negative pathogens and difficult staphylococcal infections has revived interest in the drug, and intravenous formulations are increasingly deployed in severe cases. That renewed clinical reliance inevitably applies selective pressure, and the genomic record now shows that staphylococci already possess a deep reservoir of resistance potential on which selection can act. The study’s comprehensive catalog serves as both an early-warning system and a research tool — a baseline against which future emergence and spread of fosfomycin resistance can be measured.

What emerges from the work is a picture of antibiotic resistance as a genomic ecosystem rather than a collection of isolated mutations. Staphylococci carry a diverse, layered, partially mobile arsenal of fosfomycin-inactivating genes, shaped by horizontal transfer, chromosomal stabilization and lineage-specific evolution. By decoding that repertoire in full, the researchers have given clinicians, epidemiologists and drug developers a common map of the enemy’s fortifications. Whether that map translates into better diagnostics, effective enzyme inhibitors and preservation of fosfomycin’s clinical utility will depend on the work that follows — but the study makes clear that any strategy for safeguarding this valuable antibiotic must account for a resistance repertoire far larger and more varied than previously appreciated.